


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:37Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406879" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406879</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmjo</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406879</article-id><article-id pub-id-type="pmcid-ver">PMC12406879.1</article-id><article-id pub-id-type="pmcaid">12406879</article-id><article-id pub-id-type="pmcaiid">12406879</article-id><article-id pub-id-type="pmid">40897475</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2024-096436</article-id><article-id pub-id-type="publisher-id">bmjopen-2024-096436</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Protocol</subject></subj-group><subj-group subj-group-type="heading"><subject>Mental Health</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1712</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Short-term versus long-term psychotherapy for borderline personality disorder: a protocol for an individual patient data pooled analysis of two randomised clinical trials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6171-2904</contrib-id><name name-style="western"><surname>Juul</surname><given-names initials="S">Sophie</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>McMain</surname><given-names initials="S">Shelley</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Olsen</surname><given-names initials="MH">Markus Harboe</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chapman</surname><given-names initials="A">Alexander</given-names></name><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6019-022X</contrib-id><name name-style="western"><surname>Pereira Ribeiro</surname><given-names initials="J">Johanne</given-names></name><xref rid="aff9" ref-type="aff">9</xref><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0204-7745</contrib-id><name name-style="western"><surname>Storeb&#248;</surname><given-names initials="OJ">Ole Jakob</given-names></name><xref rid="aff9" ref-type="aff">9</xref><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuo</surname><given-names initials="J">Janice</given-names></name><xref rid="aff11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0508-7929</contrib-id><name name-style="western"><surname>Hestbaek</surname><given-names initials="E">Emilie</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamp</surname><given-names initials="CB">Caroline Barkholt</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rishede</surname><given-names initials="M">Marie</given-names></name><xref rid="aff12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Frandsen</surname><given-names initials="FW">Frederik Weischer</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bo</surname><given-names initials="S">Sune</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0536-1820</contrib-id><name name-style="western"><surname>Poulsen</surname><given-names initials="S">Stig</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>S&#248;rensen</surname><given-names initials="P">Per</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bateman</surname><given-names initials="A">Anthony</given-names></name><xref rid="aff13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Simonsen</surname><given-names initials="S">Sebastian</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names initials="JC">Janus C</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff14" ref-type="aff">14</xref></contrib><aff id="aff1"><label>1</label><institution content-type="department">Copenhagen Trial Unit, Centre for Clinical Intervention Research</institution>, <institution>The Capital Region, Copenhagen University Hospital &#8211; Rigshospitalet</institution>, <addr-line content-type="city">Copenhagen</addr-line>, <country>Denmark</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Mental Health Centre Stolpegaard</institution>, <institution>Copenhagen University Hospital - Mental Health Services</institution>, <addr-line content-type="city">Copenhagen</addr-line>, <country>Denmark</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Psychology</institution>, <institution>University of Copenhagen</institution>, <addr-line content-type="city">Copenhagen</addr-line>, <country>Denmark</country></aff><aff id="aff4"><label>4</label><institution>Centre for Addiction and Mental Health</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Department of Psychiatry</institution>, <institution>University of Toronto</institution>, <addr-line content-type="city">Toronto</addr-line>, <addr-line content-type="state">Ontario</addr-line>, <country>Canada</country></aff><aff id="aff6"><label>6</label><institution content-type="department">Department of Neuroanaesthesiology</institution>, <institution>Copenhagen University Hospital &#8211; Rigshospitalet</institution>, <addr-line content-type="city">Copenhagen</addr-line>, <country>Denmark</country></aff><aff id="aff7"><label>7</label><institution content-type="department">Department of Psychology</institution>, <institution>Simon Fraser University</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff8"><label>8</label><institution>DBT Centre of Vancouver</institution>, <addr-line content-type="city">Vancouver</addr-line>, <addr-line content-type="state">British Columbia</addr-line>, <country>Canada</country></aff><aff id="aff9"><label>9</label><institution content-type="department">Center for Evidence-Based Psychiatry, Psychiatric Research Unit</institution>, <institution>Psychiatry Region Zealand, Denmark</institution>, <addr-line content-type="city">Slagelse</addr-line>, <country>Denmark</country></aff><aff id="aff10"><label>10</label><institution content-type="department">Department of Psychology</institution>, <institution>University of Southern Denmark</institution>, <addr-line content-type="city">Odense</addr-line>, <country>Denmark</country></aff><aff id="aff11"><label>11</label><institution>Department of Psychology, Palo Alto University</institution>, <addr-line content-type="city">Palo Alto</addr-line>, <addr-line content-type="state">California</addr-line>, <country>USA</country></aff><aff id="aff12"><label>12</label><institution content-type="department">Department of Psychiatry</institution>, <institution>Mental Health Services East</institution>, <addr-line content-type="city">Roskilde</addr-line>, <addr-line content-type="state">Region Zealand</addr-line>, <country>Denmark</country></aff><aff id="aff13"><label>13</label><institution>University College London</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff><aff id="aff14"><label>14</label><institution content-type="department">Department of Regional Health Research</institution>, <institution>The Faculty of Health Sciences, University of Southern Denmark</institution>, <addr-line content-type="city">Odense</addr-line>, <country>Denmark</country></aff></contrib-group><author-notes><corresp id="cor1">Dr Sophie Juul; <email xlink:href="sophie.juul@ctu.dk">sophie.juul@ctu.dk</email></corresp><fn fn-type="COI-statement" id="fn5"><p>None declared.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496158</issue-id><elocation-id>e096436</elocation-id><history><date date-type="received"><day>11</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="bmjopen-15-9.pdf"/><self-uri xlink:title="pdf" xlink:href="bmjopen-15-9.pdf"/><abstract><sec><title> Abstract</title></sec><sec><title>Background</title><p>The evidence for the optimal duration of psychotherapy for borderline personality disorder (BPD) is scarce. Two previous trials have compared different durations of psychotherapy. The first compared 6 months versus 12 months of dialectical behaviour therapy for BPD (the FASTER trial). The second compared 5 months versus 14 months of mentalisation-based therapy for BPD (the MBT-RCT trial). The primary objective of the present study will be to provide an individual patient data pooled analysis of two randomised clinical trials by combining the two short-term groups and the two long-term groups from the FASTER and MBT-RCT trials, thereby providing greater statistical power than the individual trials. Accordingly, we will evaluate the overall evidence on the effects of short-term versus long-term psychotherapy for BPD and investigate whether certain subgroups might benefit from short-term versus long-term psychotherapy.</p></sec><sec><title>Methods</title><p>An individual patient data pooled analysis of the FASTER trial and the MBT-RCT trial will be conducted. The primary outcome will be a composite of the proportion of participants with a suicide, a suicide attempt or a psychiatric hospitalisation. The secondary outcome will be the proportion of participants with self-harm. Exploratory outcomes will be BPD symptoms, symptom distress, level of functioning and quality of life. We will primarily assess outcomes at 15&#8201;months after randomisation for the FASTER trial and at 16 months after randomisation for the MBT-RCT trial. Predefined subgroups based on the design variables in the original trials will be tested for interaction with the intervention as follows: trial, sex (male compared with female), age (below or at 30 years compared with above 30 years) and baseline level of functioning (Global Assessment of Functioning baseline score at 0&#8211;49 compared with 50&#8211;100).</p></sec><sec><title>Ethics and dissemination</title><p>The statistical analyses will be performed on anonymised trial data that have already been approved by the respective ethical committees that originally assessed the included trials. The final analysis will be published in a peer-reviewed scientific journal and the results will be presented at national seminars and international conferences.</p></sec><sec><title>PROSPERO registration number</title><p>CRD42024612840.</p></sec></abstract><kwd-group><kwd>Personality disorders</kwd><kwd>PSYCHIATRY</kwd><kwd>Randomized Controlled Trial</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Trygfonden A/S</institution></institution-wrap></funding-source><award-id>123488</award-id></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Research Fund of the Mental Health Services in the Capital Region of Denmark</institution></institution-wrap></funding-source><award-id>N/A</award-id></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Canadian Institute of Health Research</institution></institution-wrap></funding-source><award-id>CIHR FRN 133428</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title></caption><list list-type="bullet" list-content="ul"><list-item><p>This will be the first individual patient data pooled analysis of two randomised clinical trials assessing the effects of short-term versus long-term psychotherapy for outpatients with borderline personality disorder.</p></list-item><list-item><p>Pooling data from two similar trials will allow us to explore potential subgroup analyses with more power than the individual trials.</p></list-item><list-item><p>Pooling dialectical behavioural therapy and mentalisation-based therapy can potentially introduce heterogeneity, which we will explore in the final analysis.</p></list-item><list-item><p>Both trials had missing outcome data, which will be a limitation of the final analysis.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Borderline personality disorder (BPD) is a serious and debilitating mental health disorder affecting 1&#8211;6% of the population.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), BPD is characterised by emotional dysregulation, interpersonal problems, identity diffusion, impulsive behaviour, chronic emptiness, intense anger, fear of abandonment and dissociative symptoms, and it is associated with exceedingly high rates of self-harm and suicide.<xref rid="R2" ref-type="bibr">2</xref><xref rid="R5" ref-type="bibr">5</xref> Patients with BPD may be highly represented in primary care settings<xref rid="R6" ref-type="bibr"><sup>6 7</sup></xref> and mental healthcare settings.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> In addition, BPD causes a significant socioeconomic burden, not only due to direct healthcare costs,<xref rid="R9" ref-type="bibr"><sup>9</sup></xref> but also due to indirect costs like social and occupational dysfunction.<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> All major guidelines for the treatment of BPD consider psychological interventions as the primary treatment of choice and assign pharmacological interventions an adjunctive role.<xref rid="R11" ref-type="bibr">11</xref><xref rid="R14" ref-type="bibr">14</xref> Even though the optimal duration of psychotherapy for BPD is unclear,<xref rid="R15" ref-type="bibr"><sup>15 16</sup></xref> it is typically long-term, lasting no less than a year in duration.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> Different short-term psychotherapies exist for patients with BPD, including brief dialectical behaviour therapy (DBT) skills training for 20 weeks,<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> emotion regulation group therapy for 14 weeks,<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> systems training for emotional predictability and problem-solving for 20 weeks,<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> mentalisation-based therapy (MBT) for 20 weeks<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> and most recently BPD Compass for 18 weeks.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> However, to assess the optimal duration of psychotherapy, randomised clinical trials must randomise participants to different lengths of psychotherapy.</p><p>A non-inferiority trial assessing the effects of 6 months versus 12 months of DBT for BPD (the FASTER trial) was recently published.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> In the FASTER trial, 240 participants were randomised to short-term or long-term DBT. Participants were adult outpatients with BPD and a minimum of one suicide attempt or act of self-harm within the past 2 months. The authors found that the non-inferiority hypothesis was supported for the primary outcome, total self-harm and several secondary outcomes. No evidence of a difference was found for serious or non-serious adverse events.</p><p>A similar trial was recently published assessing the effects of 5 months versus 14 months of MBT for BPD (the MBT-RCT trial).<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> In the MBT-RCT trial, 166 participants were randomised to short-term MBT or long-term MBT. Participants were adult outpatients with subthreshold (at least four DSM-5 criteria) or diagnosed BPD. The authors found no evidence of a difference between short-term versus long-term MBT on the primary outcome, borderline symptoms or any of the secondary outcomes. More participants in the long-term MBT group had a serious adverse event compared with short-term MBT, primarily driven by a difference in psychiatric hospitalisations, but the result was not statistically significant.</p><p>In both the FASTER trial and the MBT-RCT trial, the short-term and the long-term interventions were relatively similar in lengths, the participants were all adult BPD outpatients, and the trials had similar methodologies which were predefined and protocolised.<xref rid="R24" ref-type="bibr"><sup>24 25</sup></xref> The primary objective of the present study will be to provide an individual patient pooled analysis of the results of the FASTER trial and the MBT-RCT trial by combining the two short-term groups and the two long-term groups, thereby providing greater statistical power than the individual trials. Accordingly, we will evaluate the overall evidence on the effect of short-term vs long-term psychotherapy for BPD and investigate whether specific subgroups might benefit from short-term versus long-term psychotherapy.</p></sec><sec sec-type="methods|materials" id="s2"><title>Methods and materials</title><p>This protocol was pre-registered in the PROSPERO database (registration ID: CRD42024612840). The final analysis will be conducted in accordance with this protocol, which was written and registered before analysis, and any deviations will be reported.</p><sec id="s2-1"><title>Study design</title><p>The design and results of the FASTER and MBT-RCT trials were published previously.<xref rid="R21" ref-type="bibr">2123</xref><xref rid="R26" ref-type="bibr">26</xref> In short, the population in both trials was adults with BPD. The FASTER trial compared 6 months versus 12 months of DBT for adult outpatients with BPD and assessed the effects every 3 months from randomisation to 24 months. The FASTER trial was a multicentre trial conducted at two sites: the BPD Clinic at the Centre for Addiction and Mental Health in Toronto, Canada, and the Personality and Emotion Research Laboratory in conjunction with the DBT Centre in Vancouver, British Columbia (clinicaltrials.gov registration number: <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT02387736">NCT02387736</ext-link>; February 2015).<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> The MBT-RCT trial compared 5 months versus 14 months MBT for adult outpatients with BPD and assessed the effects at 8 months, 16 months and 24 months after randomisation. The MBT-RCT trial was a single-centre trial conducted at the Outpatient Clinic for Personality Disorders at Stolpegaard Psychotherapy Centre in The Capital Region of Denmark (clinicaltrials.gov registration number: <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT03677037">NCT03677037</ext-link>; September 2018).<xref rid="R24" ref-type="bibr"><sup>24 26</sup></xref> Separate ethics approval for this study was not required, as each trial was approved by ethics committees and authorities in each participating country.</p></sec><sec id="s2-2"><title>Outcomes</title><p>Outcomes for the individual patient data pooled analysis will be defined as primary, secondary or exploratory.</p><sec id="s2-2-1"><title>Primary outcome</title><list list-type="bullet" list-content="ul"><list-item><p>Proportion of participants with either a suicide, a suicide attempt or a psychiatric hospitalisation (composite outcome, dichotomous data).</p></list-item></list></sec><sec id="s2-2-2"><title>Secondary outcome</title><list list-type="bullet" list-content="ul"><list-item><p>Proportion of participants with deliberate self-harm (dichotomous data). Self-harm will be defined as deliberate acts of self-harm with the conscious intent to cause self-injury or to risk self-injury, for example, alcohol and/or drug consumption with the intention of self-injury, poison, burning, scratching/cutting, stabbing/puncture, gun shooting, hanging, strangling.</p></list-item></list></sec><sec id="s2-2-3"><title>Exploratory outcomes</title><list list-type="bullet" list-content="ul"><list-item><p>BPD symptom severity assessed with the Zanarini Rating Scale for BPD (ZAN-BPD) or the Borderline Symptom List-23 (continuous data).</p></list-item><list-item><p>Quality of life assessed with the Short-form Health Survey-36 mental component or the Euroqol-5D-5 Level (continuous data)</p></list-item><list-item><p>Level of functioning assessed with the Global Assessment of Functioning (GAF) or the Social Adjustment Scale Self-Report (continuous data).</p></list-item><list-item><p>Symptom distress assessed with the Global Severity Index of the Symptom Checklist-90 (continuous data).</p></list-item><list-item><p>Each of the components of the primary composite outcome will be analysed as exploratory outcomes.</p></list-item></list></sec><sec id="s2-2-4"><title>Time points of assessment</title><p>Our primary time point will be the 15&#8201;months after randomisation time point for the FASTER trial and the 16 months after randomisation time point for the MBT-RCT trial. As a secondary analysis, we will assess outcomes at 24 months after randomisation in both trials.</p></sec></sec><sec id="s2-3"><title>Risk of bias and certainty of evidence</title><p>Risk of bias will be assessed with the Cochrane Risk of Bias tool &#8211; V.2,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref> and certainty of the evidence will be assessed with the Grading of Recommendations, Assessment, Development and Evaluations.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></p></sec><sec id="s2-4"><title>Statistical analysis plan</title><sec id="s2-4-1"><title>General analysis principles</title><p>All analyses will be conducted according to the intention-to-treat principle. We will both assess if the thresholds for statistical significance and clinical significance are crossed, and Bayes factor calculations will be reported.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Assessments of clinical significance will be based on the anticipated intervention effects used in the sample size/power estimations in the MBT trial.<xref rid="R26" ref-type="bibr"><sup>26 29</sup></xref> Our primary conclusion will be based on the primary outcome, so all tests of statistical significance (including subgroup analyses) will be two-sided with a type I error risk of 5%.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></p><p>It is generally acknowledged that regression analyses ought to be adjusted for the stratification variables used in the randomisation.<xref rid="R30" ref-type="bibr">30</xref><xref rid="R32" ref-type="bibr">32</xref> The FASTER trial used &#8216;site&#8217; as a stratification variable, and the MBT-RCT used sex (male/female) and high versus low baseline scores on the primary outcome, ZAN-BPD, as the stratification variables. We will adjust all regression analyses for &#8216;trial site&#8217;. We will also assess whether there are significant interactions between trial interventions and &#8216;site&#8217; (see the &#8216;Assessments of underlying statistical assumptions&#8217; section).</p><p>We will also perform the following subgroup analyses for all primary and secondary outcomes: trial, sex (male compared with female), age (below or at 30 years compared with above 30 years) and baseline level of functioning (GAF baseline score at 0&#8211;49 compared with 50&#8211;100). We will present the subgroup results in forest plots. We will additionally include the continuous subgroup variables as continuous variables in regression analyses to assess if the tests of interaction are significant.</p></sec><sec id="s2-4-2"><title>Analysis of dichotomous data</title><p>Dichotomised outcomes will be presented as proportions of participants in each group with events and risk ratios with 95% CIs. Dichotomous outcomes will be analysed using generalised linear models using a log link function. If the model does not converge, we will try a different optimisation technique or use a logit-link model if possible.</p></sec><sec id="s2-4-3"><title>Analysis of continuous data</title><p>Continuous outcomes will be presented as means, SD and 95% confidence levels in each group and analysed using linear regression.</p></sec><sec id="s2-4-4"><title>Handling of missing data</title><p>All randomised participants with available data will be included in the primary analysis according to the intention-to-treat principle. We anticipate that the proportion of missing values will be less than 5% for the dichotomous outcomes. We expect large proportions of missing data for the continuous outcomes. Missing data will be handled according to the recommendation by Jakobsen <italic toggle="yes">et al</italic>.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> In short, in secondary analyses, we will consider using multiple imputation and/or present best-worst and worst-best case scenarios if it is not valid to ignore missing data.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> Best-worst and worst-best case scenarios assess the potential range of impact of the missing data for the trial results.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> In the &#8216;best-worst&#8217; case scenario, it is assumed that all patients lost to follow-up in the short-term group have had a beneficial outcome (have survived, had no poor functional outcome and so forth), and all those with missing outcomes in the long-term group have had a harmful outcome (have not survived, have had poor functional outcome and so forth).<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> Conversely, in the &#8216;worst-best&#8217; case scenario, it is assumed that all patients who were lost to follow-up in the experimental group have had a harmful outcome and that all those lost to follow-up in the control group have had a beneficial outcome.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref></p></sec><sec id="s2-4-5"><title>Aggregate data meta-analysis</title><p>The two trials used two different scales to assess BPD symptom severity, quality of life and level of functioning, and we will pool them using standardised mean difference meta-analysis statistics. We will undertake the meta-analyses according to the <italic toggle="yes">Cochrane Handbook of Systematic Reviews of Interventions</italic>,<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> Keus <italic toggle="yes">et al</italic><xref rid="R35" ref-type="bibr"><sup>35</sup></xref> and the eight-step assessment suggested by Jakobsen <italic toggle="yes">et al</italic>.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref> We will use the statistical software Stata V.16<xref rid="R37" ref-type="bibr"><sup>37</sup></xref> (command: meta) and R to analyse data. We will assess the intervention effect with both random-effects and fixed-effect meta-analysis. We will primarily report the most conservative results (highest p values) of the two and consider the less conservative results as a sensitivity analysis.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref> Our primary conclusion will be based on the primary outcome; hence, we will not adjust the significance level according to multiplicity.</p></sec><sec id="s2-4-6"><title>Trial sequential analysis</title><p>Traditional meta-analysis runs the risk of random errors due to sparse data and repetitive testing of accumulating data when updating reviews. To control the risks of type I errors and type II errors, we will perform Trial Sequential Analysis on the primary and secondary outcomes, in order to calculate the diversity-adjusted required information size (that is, the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) and the cumulative Z-curve&#8217;s breach of relevant trial sequential monitoring boundaries.<xref rid="R38" ref-type="bibr">38</xref><xref rid="R46" ref-type="bibr">46</xref> A more detailed description of Trial Sequential Analysis software can be found in the manual<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> and at <ext-link xlink:href="http://www.ctu.dk/tsa/" ext-link-type="uri">http://www.ctu.dk/tsa/</ext-link>. For the primary and secondary outcomes, which are both dichotomous outcomes, we will estimate the required information size based on the observed proportion of patients with an outcome in the control group (the cumulative proportion of patients with an event in the control groups relative to all patients in the control groups), a relative risk reduction or a relative risk increase of 25%, an alpha of 5% for all our outcomes, a beta of 20% and the observed diversity as suggested by the trials in the meta-analysis.</p></sec><sec id="s2-4-7"><title>Assessments of underlying statistical assumptions</title><p>We will systematically assess underlying statistical assumptions for all statistical analyses.<xref rid="R47" ref-type="bibr"><sup>47 48</sup></xref> For <italic toggle="yes">all</italic> regression analyses, both primary and secondary, we will test for major interactions between &#8216;trial site&#8217; and the intervention variable and whether the interactions show a clinically important effect. If it is concluded that the interaction is significant, we will consider both presenting an analysis separately for each site and an overall analysis including the interaction term in the model.<xref rid="R47" ref-type="bibr"><sup>47 48</sup></xref></p></sec><sec id="s2-4-8"><title>Assessments of underlying statistical assumptions for dichotomous outcomes</title><p>We will assess if the deviance by the df is significantly larger than one to assess for relevant overdispersion, that is, the presence of greater variability (statistical dispersion) in a data set than would be expected based on a given statistical model. If this is the case, we will consider using the maximum likelihood estimate of the dispersion parameter.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></p></sec><sec id="s2-4-9"><title>Assessments of underlying statistical assumptions for continuous outcomes</title><p>We will visually inspect quantile-quantile plots of the residuals<xref rid="R49" ref-type="bibr"><sup>49 50</sup></xref> to assess if the residuals are normally distributed and use residuals plotted against covariates and fitted values<xref rid="R49" ref-type="bibr"><sup>49 50</sup></xref> to assess for homogeneity of variances. If the plots show deviations from the model assumptions, we will consider transforming the outcome, for example, using log transformation or square root and/or using robust SEs.<xref rid="R49" ref-type="bibr"><sup>49 50</sup></xref></p></sec><sec id="s2-4-10"><title>Statistical reports</title><p>Data on all outcomes will be analysed by two independent individuals.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> Two independent statistical reports will be sent to the chief principal investigator (SJ) and will be shared with the author group. If there are discrepancies between the two primary statistical reports, then possible reasons for that will be identified, and the author group will decide which is the most correct result. A final statistical report will be prepared, and all three statistical reports will be published as supplementary material.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref></p></sec><sec id="s2-4-11"><title>Public and patient involvement</title><p>Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.</p></sec></sec></sec><sec id="s3"><title>Ethics and dissemination</title><p>The statistical analyses will be performed on fully anonymised trial data that have already been approved by the respective ethical committees that originally assessed the included trials in the respective countries. The final individual patient data pooled analysis will be published in a peer-reviewed scientific journal and the results will be presented at Danish national seminars and at international conferences.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> Canadian Institute of Health Research (CIHR FRN 133428) funded the FASTER trial. TrygFonden A/S (grant no. 123488) and the Research Fund of the Mental Health Services in the Capital Region of Denmark (grant no. N/A) funded the MBT-RCT trial. The Research Fund of the Mental Health Services in the Capital Region of Denmark (grant no. N/A) funded the present study. The funders have no role in the design, data collection, data analysis and reporting of this study.</p></fn><fn fn-type="other"><p>Prepublication history for this paper is available online. To view these files, please visit the journal online (<ext-link xlink:href="https://doi.org/10.1136/bmjopen-2024-096436" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2024-096436</ext-link>).</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torgersen</surname><given-names>S</given-names></name><name name-style="western"><surname>Kringlen</surname><given-names>E</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>V</given-names></name></person-group><article-title>The prevalence of personality disorders in a community sample</article-title><source>Arch Gen Psychiatry</source><year>2001</year><volume>58</volume><fpage>590</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.58.6.590</pub-id><pub-id pub-id-type="pmid">11386989</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>AT</given-names></name><name name-style="western"><surname>Mann</surname><given-names>AH</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KA</given-names></name></person-group><article-title>Personality disorder and suicide. A case-control study</article-title><source>Br J Psychiatry</source><year>1997</year><volume>170</volume><fpage>441</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1192/bjp.170.5.441</pub-id><pub-id pub-id-type="pmid">9307694</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lesage</surname><given-names>AD</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>R</given-names></name><name name-style="western"><surname>Grunberg</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Suicide and mental disorders: a case-control study of young men</article-title><source>Am J Psychiatry</source><year>1994</year><volume>151</volume><fpage>1063</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1176/ajp.151.7.1063</pub-id><pub-id pub-id-type="pmid">7503818</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>DW</given-names></name><name name-style="western"><surname>Blum</surname><given-names>N</given-names></name><name name-style="western"><surname>Pfohl</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Suicidal Behavior in Borderline Personality Disorder: Prevalence, Risk Factors, Prediction, and Prevention</article-title><source>J Pers Disord</source><year>2004</year><volume>18</volume><fpage>226</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1521/pedi.18.3.226.35445</pub-id><pub-id pub-id-type="pmid">15237043</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><article-title>Diagnostic and statistical manual of mental disorders (DSM-5&#174;). Report No.: 0890425574</article-title><publisher-name>American Psychiatric Pub</publisher-name><year>2013</year></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gross</surname><given-names>R</given-names></name><name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gameroff</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Borderline personality disorder in primary care</article-title><source>Arch Intern Med</source><year>2002</year><volume>162</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1001/archinte.162.1.53</pub-id><pub-id pub-id-type="pmid">11784220</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellison</surname><given-names>WD</given-names></name><name name-style="western"><surname>Rosenstein</surname><given-names>LK</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>TA</given-names></name><etal>et al</etal></person-group><article-title>Community and Clinical Epidemiology of Borderline Personality Disorder</article-title><source>Psychiatr Clin North Am</source><year>2018</year><volume>41</volume><fpage>561</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.psc.2018.07.008</pub-id><pub-id pub-id-type="pmid">30447724</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanarini</surname><given-names>MC</given-names></name><name name-style="western"><surname>Frankenburg</surname><given-names>FR</given-names></name><name name-style="western"><surname>Hennen</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years</article-title><source>J Clin Psychiatry</source><year>2004</year><volume>65</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.4088/jcp.v65n0105</pub-id><pub-id pub-id-type="pmid">14744165</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soeteman</surname><given-names>DI</given-names></name><name name-style="western"><surname>Hakkaart-van Roijen</surname><given-names>L</given-names></name><name name-style="western"><surname>Verheul</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>The economic burden of personality disorders in mental health care</article-title><source>J Clin Psychiatry</source><year>2008</year><volume>69</volume><fpage>259</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.4088/jcp.v69n0212</pub-id><pub-id pub-id-type="pmid">18363454</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sansone</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>LA</given-names></name></person-group><article-title>Employment in borderline personality disorder</article-title><source>Innov Clin Neurosci</source><year>2012</year><volume>9</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1521/pedi.2011.25.6.782</pub-id><pub-id pub-id-type="pmcid">PMC3472897</pub-id><pub-id pub-id-type="pmid">23074700</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence (NICE)</collab></person-group><article-title>Borderline personality disorder: recognition and management</article-title><year>2009</year><comment>Available</comment><ext-link xlink:href="https://www.nice.org.uk/guidance/cg78" ext-link-type="uri">https://www.nice.org.uk/guidance/cg78</ext-link><comment>Accessed</comment><date-in-citation>19-Sep-2022</date-in-citation><pub-id pub-id-type="pmid">39480982</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Psychological Association</collab></person-group><article-title>Diagnostic and statistical manual of mental disorders</article-title><source>Am Psychiatric Assoc</source><year>2013</year><volume>21</volume><fpage>591</fpage><lpage>643</lpage><comment>Available</comment><ext-link xlink:href="https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596" ext-link-type="uri">https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596</ext-link></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Health Medical Research Council</collab></person-group><source>Clinical practice guideline for the management of borderline personality disorder</source><publisher-loc>Melbourne</publisher-loc><publisher-name>NHMRC</publisher-name><year>2012</year></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoffers-Winterling</surname><given-names>JM</given-names></name><name name-style="western"><surname>Storeb&#248;</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Pereira Ribeiro</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Pharmacological interventions for people with borderline personality disorder</article-title><source>Cochrane Database Syst Rev</source><year>2022</year><volume>11</volume><elocation-id>CD012956</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD012956.pub2</pub-id><pub-id pub-id-type="pmid">36375174</pub-id><pub-id pub-id-type="pmcid">PMC9662763</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juul</surname><given-names>S</given-names></name><name name-style="western"><surname>Poulsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Lunn</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Short-term versus long-term psychotherapy for adult psychiatric disorders: a protocol for a systematic review with meta-analysis and trial sequential analysis</article-title><source>Syst Rev</source><year>2019</year><volume>8</volume><elocation-id>169</elocation-id><pub-id pub-id-type="doi">10.1186/s13643-019-1099-0</pub-id><pub-id pub-id-type="pmid">31301732</pub-id><pub-id pub-id-type="pmcid">PMC6626421</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juul</surname><given-names>S</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>JC</given-names></name><name name-style="western"><surname>J&#248;rgensen</surname><given-names>CK</given-names></name><etal>et al</etal></person-group><article-title>The difference between shorter- versus longer-term psychotherapy for adult mental health disorders: a systematic review with meta-analysis</article-title><source>BMC Psychiatry</source><year>2023</year><volume>23</volume><elocation-id>438</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-023-04895-6</pub-id><pub-id pub-id-type="pmid">37328755</pub-id><pub-id pub-id-type="pmcid">PMC10273498</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storeb&#248;</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Stoffers-Winterling</surname><given-names>JM</given-names></name><name name-style="western"><surname>V&#246;llm</surname><given-names>BA</given-names></name><etal>et al</etal></person-group><article-title>Psychological therapies for people with borderline personality disorder</article-title><source>Cochrane Database Syst Rev</source><year>2020</year><volume>5</volume><elocation-id>CD012955</elocation-id><pub-id pub-id-type="doi">10.1002/14651858.CD012955.pub2</pub-id><pub-id pub-id-type="pmid">32368793</pub-id><pub-id pub-id-type="pmcid">PMC7199382</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMain</surname><given-names>SF</given-names></name><name name-style="western"><surname>Guimond</surname><given-names>T</given-names></name><name name-style="western"><surname>Barnhart</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>A randomized trial of brief dialectical behaviour therapy skills training in suicidal patients suffering from borderline disorder</article-title><source>Acta Psychiatr Scand</source><year>2017</year><volume>135</volume><fpage>138</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1111/acps.12664</pub-id><pub-id pub-id-type="pmid">27858962</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gratz</surname><given-names>KL</given-names></name><name name-style="western"><surname>Tull</surname><given-names>MT</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder</article-title><source>Psychol Med</source><year>2014</year><volume>44</volume><fpage>2099</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1017/S0033291713002134</pub-id><pub-id pub-id-type="pmid">23985088</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>N</given-names></name><name name-style="western"><surname>St John</surname><given-names>D</given-names></name><name name-style="western"><surname>Pfohl</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up</article-title><source>Am J Psychiatry</source><year>2008</year><volume>165</volume><fpage>468</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2007.07071079</pub-id><pub-id pub-id-type="pmid">18281407</pub-id><pub-id pub-id-type="pmcid">PMC3608469</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juul</surname><given-names>S</given-names></name><name name-style="western"><surname>Jakobsen</surname><given-names>JC</given-names></name><name name-style="western"><surname>Hestbaek</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Short-Term versus Long-Term Mentalization-Based Therapy for Borderline Personality Disorder: A Randomized Clinical Trial (MBT-RCT)</article-title><source>Psychother Psychosom</source><year>2023</year><volume>92</volume><fpage>329</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1159/000534289</pub-id><pub-id pub-id-type="pmid">37935133</pub-id><pub-id pub-id-type="pmcid">PMC10716869</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sauer-Zavala</surname><given-names>S</given-names></name><name name-style="western"><surname>Southward</surname><given-names>MW</given-names></name><name name-style="western"><surname>Fruhbauerova</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>BPD compass: A randomized controlled trial of a short-term, personality-based treatment for borderline personality disorder</article-title><source>Personal Disord</source><year>2023</year><volume>14</volume><fpage>534</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1037/per0000612</pub-id><pub-id pub-id-type="pmid">36595435</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMain</surname><given-names>SF</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>The Effectiveness of 6 versus 12 Months of Dialectical Behavior Therapy for Borderline Personality Disorder: A Noninferiority Randomized Clinical Trial</article-title><source>Psychother Psychosom</source><year>2022</year><volume>91</volume><fpage>382</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1159/000525102</pub-id><pub-id pub-id-type="pmid">35738244</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juul</surname><given-names>S</given-names></name><name name-style="western"><surname>Lunn</surname><given-names>S</given-names></name><name name-style="western"><surname>Poulsen</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Short-term versus long-term mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder: a protocol for a randomized clinical trial</article-title><source>Trials</source><year>2019</year><volume>20</volume><elocation-id>196</elocation-id><pub-id pub-id-type="doi">10.1186/s13063-019-3306-7</pub-id><pub-id pub-id-type="pmid">30953536</pub-id><pub-id pub-id-type="pmcid">PMC6451226</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMain</surname><given-names>SF</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder: the feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol</article-title><source>BMC Psychiatry</source><year>2018</year><volume>18</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/s12888-018-1802-z</pub-id><pub-id pub-id-type="pmid">30016935</pub-id><pub-id pub-id-type="pmcid">PMC6050694</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juul</surname><given-names>S</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>S</given-names></name><name name-style="western"><surname>Poulsen</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Detailed statistical analysis plan for the short-term versus long-term mentalisation-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder randomised clinical trial (MBT-RCT)</article-title><source>Trials</source><year>2021</year><volume>22</volume><elocation-id>497</elocation-id><pub-id pub-id-type="doi">10.1186/s13063-021-05450-y</pub-id><pub-id pub-id-type="pmid">34321051</pub-id><pub-id pub-id-type="pmcid">PMC8316699</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>JAC</given-names></name><name name-style="western"><surname>Savovi&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><etal>et al</etal></person-group><article-title>RoB 2: a revised tool for assessing risk of bias in randomised trials</article-title><source>BMJ</source><year>2019</year><volume>366</volume><elocation-id>l4898</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id><pub-id pub-id-type="pmid">31462531</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guyatt</surname><given-names>GH</given-names></name><name name-style="western"><surname>Oxman</surname><given-names>AD</given-names></name><name name-style="western"><surname>Kunz</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>GRADE guidelines: 2. Framing the question and deciding on important outcomes</article-title><source>J Clin Epidemiol</source><year>2011</year><volume>64</volume><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2010.09.012</pub-id><pub-id pub-id-type="pmid">21194891</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>C</given-names></name><name name-style="western"><surname>Winkel</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials</article-title><source>BMC Med Res Methodol</source><year>2014</year><volume>14</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-14-34</pub-id><pub-id pub-id-type="pmid">24588900</pub-id><pub-id pub-id-type="pmcid">PMC4015863</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahan</surname><given-names>BC</given-names></name><name name-style="western"><surname>Morris</surname><given-names>TP</given-names></name></person-group><article-title>Improper analysis of trials randomised using stratified blocks or minimisation</article-title><source>Stat Med</source><year>2012</year><volume>31</volume><fpage>328</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/sim.4431</pub-id><pub-id pub-id-type="pmid">22139891</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kahan</surname><given-names>BC</given-names></name><name name-style="western"><surname>Morris</surname><given-names>TP</given-names></name></person-group><article-title>Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis</article-title><source>BMJ</source><year>2012</year><volume>345</volume><elocation-id>e5840</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.e5840</pub-id><pub-id pub-id-type="pmid">22983531</pub-id><pub-id pub-id-type="pmcid">PMC3444136</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>AA</given-names></name><name name-style="western"><surname>Peters</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Little</surname><given-names>P</given-names></name></person-group><article-title>Design, analysis and presentation of factorial randomised controlled trials</article-title><source>BMC Med Res Methodol</source><year>2003</year><volume>3</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-3-26</pub-id><pub-id pub-id-type="pmid">14633287</pub-id><pub-id pub-id-type="pmcid">PMC305359</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names>JC</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>C</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts</article-title><source>BMC Med Res Methodol</source><year>2017</year><volume>17</volume><elocation-id>162</elocation-id><pub-id pub-id-type="doi">10.1186/s12874-017-0442-1</pub-id><pub-id pub-id-type="pmid">29207961</pub-id><pub-id pub-id-type="pmcid">PMC5717805</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>J</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>J</given-names></name></person-group><source>Cochrane handbook for systematic reviews of interventions version 6.0 (Updated July 2019)</source><publisher-name>Cochrane</publisher-name><year>2019</year><comment>Available</comment><ext-link xlink:href="https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604" ext-link-type="uri">https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604</ext-link></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keus</surname><given-names>F</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Evidence at a glance: error matrix approach for overviewing available evidence</article-title><source>BMC Med Res Methodol</source><year>2010</year><volume>10</volume><elocation-id>90</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-10-90</pub-id><pub-id pub-id-type="pmid">20920306</pub-id><pub-id pub-id-type="pmcid">PMC2959031</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakobsen</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><name name-style="western"><surname>Winkel</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods</article-title><source>BMC Med Res Methodol</source><year>2014</year><volume>14</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-14-120</pub-id><pub-id pub-id-type="pmid">25416419</pub-id><pub-id pub-id-type="pmcid">PMC4251848</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>StataCorp</collab></person-group><article-title>Stata statistical software: release 16</article-title><publisher-loc>College Station, TX</publisher-loc><publisher-name>StataCorp LLC</publisher-name><year>2019</year><comment>Available</comment><ext-link xlink:href="http://www.stata.com" ext-link-type="uri">http://www.stata.com</ext-link></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Copenhagen Trial Unit</collab></person-group><article-title>TSA - trial sequential analysis</article-title><comment>n.d.</comment><comment>Available</comment><ext-link xlink:href="http://www.ctu.dk/tsa/" ext-link-type="uri">http://www.ctu.dk/tsa/</ext-link></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Brok</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>61</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.03.013</pub-id><pub-id pub-id-type="pmid">18083463</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brok</surname><given-names>J</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</article-title><source>J Clin Epidemiol</source><year>2008</year><volume>61</volume><fpage>763</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2007.10.007</pub-id><pub-id pub-id-type="pmid">18411040</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brok</surname><given-names>J</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</article-title><source>Int J Epidemiol</source><year>2009</year><volume>38</volume><fpage>287</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1093/ije/dyn188</pub-id><pub-id pub-id-type="pmid">18824466</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Devereaux</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</article-title><source>Int J Epidemiol</source><year>2009</year><volume>38</volume><fpage>276</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1093/ije/dyn179</pub-id><pub-id pub-id-type="pmid">18824467</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Brok</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Estimating required information size by quantifying diversity in random-effects model meta-analyses</article-title><source>BMC Med Res Methodol</source><year>2009</year><volume>9</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2288-9-86</pub-id><pub-id pub-id-type="pmid">20042080</pub-id><pub-id pub-id-type="pmcid">PMC2809074</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Engstr&#248;m</surname><given-names>J</given-names></name><name name-style="western"><surname>Wetterslev</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>User manual for trial sequential analysis (TSA)</article-title><year>2011</year><comment>Available</comment><ext-link xlink:href="http://wwwctudk/tsa/files/tsa_manualpdf" ext-link-type="uri">http://wwwctudk/tsa/files/tsa_manualpdf</ext-link></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Anema</surname><given-names>A</given-names></name><name name-style="western"><surname>Mills</surname><given-names>E</given-names></name></person-group><article-title>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</article-title><source>Clin Epidemiol</source><year>2010</year><volume>2</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2147/clep.s9242</pub-id><pub-id pub-id-type="pmid">20865104</pub-id><pub-id pub-id-type="pmcid">PMC2943189</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imberger</surname><given-names>G</given-names></name><name name-style="western"><surname>Thorlund</surname><given-names>K</given-names></name><name name-style="western"><surname>Gluud</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><elocation-id>e011890</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2016-011890</pub-id><pub-id pub-id-type="pmcid">PMC4985805</pub-id><pub-id pub-id-type="pmid">27519923</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>EE</given-names></name><name name-style="western"><surname>N&#248;rskov</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lange</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Assessing assumptions for statistical analyses in randomised clinical trials</article-title><source>BMJ Evid Based Med</source><year>2019</year><volume>24</volume><fpage>185</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/bmjebm-2019-111174</pub-id><pub-id pub-id-type="pmid">30948454</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#248;rskov</surname><given-names>AK</given-names></name><name name-style="western"><surname>Lange</surname><given-names>T</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>EE</given-names></name><etal>et al</etal></person-group><article-title>Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how</article-title><source><italic toggle="yes">BMJ Evid Based Med</italic></source><year>2021</year><volume>26</volume><fpage>121</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/bmjebm-2019-111268</pub-id><pub-id pub-id-type="pmid">31988195</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Frydenberg</surname><given-names>Sj</given-names></name></person-group><source>An introduction to stata for health researchers</source><edition>4th</edition><comment>edn</comment><publisher-name>Stata Press</publisher-name><year>2014</year></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>AG</given-names></name></person-group><source>Biostatistics decoded</source><publisher-name>Wiley</publisher-name><year>2013</year></element-citation></ref></ref-list></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date></front-stub><body><fig id="d67e1903" position="anchor" orientation="portrait"><media xlink:href="bmjopen-2024-096436.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>